Piperazine compounds as inhibitors of MMP or TNF
First Claim
14. A method of treating and/or preventing a MMP- or TNFα
- -mediated disease which comprises administering an effective amount of the compound of following formula (I) or a pharmaceutically acceptable salt thereof to a human being or an animal
0 Assignments
0 Petitions
Accused Products
Abstract
A compound of formula (I) wherein A is a sulfonyl or a carbonyl; R 1 is an optionally substituted aryl, an optionally substituted heterocyclic group, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; R 2 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R 3 is an optionally substituted lower alkyl, an optionally substituted lower alkoxy, an optionally substituted aryloxy, an optionally substitued lower alkenyl, an optionally substituted aryl, an optionally substituted heterocyclic group or an optionally substitued amino, R 4 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group, R 5 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; and R 10 is a hydroxy or a protected hydroxy, and a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a medicament for prophylactic and therapeutic treatment of MMP- or TNF±-mediated diseases.
21 Citations
35 Claims
-
14. A method of treating and/or preventing a MMP- or TNFα
- -mediated disease which comprises administering an effective amount of the compound of following formula (I) or a pharmaceutically acceptable salt thereof to a human being or an animal
- View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)
Specification